Phase 3, Multicenter, Randomized, Open-Label,Active-Controlled Study of the Efficacy and Safety of FG-4592 (Roxadustat) in the Treatment of Anemia in Incident-Dialysis Patients
Phase of Trial: Phase III
Latest Information Update: 11 May 2017
At a glance
- Drugs Roxadustat (Primary) ; Epoetin alfa
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms HIMALAYAS
- Sponsors FibroGen
- 04 May 2017 Planned number of patients changed from 750 to 900.
- 04 May 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
- 04 May 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.